'Liquid biopsy' predicts lymphoma therapy success within days, study finds

August 20, 2018, Stanford University Medical Center
Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0

A blood test can predict which patients with a type of cancer called diffuse large B cell lymphoma are likely to respond positively to initial therapy and which are likely to need more aggressive treatment, according to a multicenter study led by researchers at the Stanford University School of Medicine.

The study validates the clinical usefulness of tracking the rise and fall of circulating tumor DNA, or ctDNA, in the blood of patients before and after . It suggests that clinicians may soon be able to determine how a patient is responding to treatment within days or weeks of starting therapy rather than waiting until therapy is completed five to six months later.

"Although can cure the majority of patients with even advanced B cell lymphomas, some don't respond to initial treatment," said associate professor of medicine Ash Alizadeh, MD, Ph.D. "But we don't know which ones until several months have passed. Now we can predict nonresponders within 21 days after the initiation of treatment by tracking the levels of ctDNA in a patient's blood. We can look earlier and make a reliable prediction about outcome."

The study will be published online Aug. 20 in the Journal of Clinical Oncology. Alizadeh shares senior authorship with associate professor of radiation oncology Maximilian Diehn, MD, Ph.D. Instructor of medicine David Kurtz, MD, Ph.D., and postdoctoral scholar Florian Scherer, MD, are the lead authors.

Varying responses to treatment

Diffuse large B cell lymphoma, a blood , is the most common type of non-Hodgkin lymphoma. Because it is highly biologically variable, patients vary widely in their response to treatment. Although most people are cured by conventional therapy, about one-third are not. Being able to predict early in the course of treatment those who will need additional or more aggressive therapies would be a significant boon to both clinicians and patients.

Circulating tumor DNA is released into the blood by dying cancer cells. Learning to pick out and read these DNA sequences among the thousands or even millions of other noncancerous sequences in the blood can provide valuable insight into the course of the disease and the effectiveness of therapy. Recently, Diehn and Alizadeh showed that ctDNA tracking can also predict lung cancer recurrence weeks or months before any clinical symptoms arise.

"Combined with our recent study on lung cancer, our new findings speak to the power and likely utility of using ctDNA to assess how well cancer treatments are working in an individual patient. We are very hopeful that the approach will ultimately be extensible to most if not all cancer types," Diehn said.

In this study, the researchers tracked ctDNA levels in 217 people with diffuse large B cell lymphoma who were treated at six medical centers—three in the United States and three in Europe. For each patient, they compared levels of ctDNA before treatment began with the levels after the first and second rounds of conventional chemotherapy. They then correlated those changes with each patient's outcome.

They found that ctDNA was detectable prior to the initiation of therapy in 98 percent of the people studied. And, as would be expected, the amount of ctDNA in the blood dropped in all patients once began. But the precipitousness of the decline varied. Those people whose ctDNA levels dropped a hundredfold after the first round or three-hundredfold by the second round were much more likely to live 24 months or more without experiencing a recurrence of their disease than those whose ctDNA levels declined more slowly.

"We found that ctDNA levels serve as a very sensitive and specific biomarker of response to therapy within as few as 21 days," Kurtz said. "Every year, about 30,000 people in the United States are diagnosed with diffuse large B and, for the most part, they're treated with six cycles of combination therapy. But we know that not all patients need six cycles. A large fraction could be cured with fewer cycles—maybe even just two. If we can identify those people who are responding extremely well, we could spare them additional treatments. Conversely, we could intensify the therapy or seek other options for those who are not responding as well as we would have hoped."

Hopes for expansion

The researchers are encouraged that they saw a similar correlation between changes in ctDNA levels and outcomes in patients from each of the six participating medical centers, confirming the global usefulness of the analysis. They're currently planning a clinical trial based on the results, and they're eager to learn whether they can make similar predictions about the prognoses of patients other than those with diffuse large B cell lymphomas.

"These findings confirm the value of tracking cancer genetics in the in real time," Alizadeh said. "We are thinking about how to use the tools to best benefit , and are very excited to test this approach in other types of cancers."

Explore further: DNA sequencing determines lymphoma origin, prognosis

Related Stories

DNA sequencing determines lymphoma origin, prognosis

November 9, 2016
Sequencing tiny bits of DNA circulating in the blood of patients with lymphoma can accurately identify the cancer subtype and pinpoint mutations that might cause drug resistance, according to researchers at the Stanford University ...

Limited evidence for clinical validity, utility of ctDNA

March 5, 2018
(HealthDay)—There is little evidence for the clinical validity or utility of circulating tumor DNA (ctDNA) assays for solid tumors, according to a special article published online March 5 in the Journal of Clinical Oncology.

Levels of DNA in blood test correlated with ovarian cancer outcomes

December 20, 2016
Levels of circulating tumor DNA (ctDNA) detected in a blood test are correlated with the size of ovarian cancers and can predict a patient's response to treatment or time to disease progression, according to a retrospective ...

Circulating tumor DNA in blood can predict recurrence of the most common type of lymphoma

April 3, 2015
Measurement of circulating tumor DNA (ctDNA) in blood can be used to detect disease recurrence in patients with a curable form of cancer known as diffuse large B-cell lymphoma (DLBCL). In most patients, measurement of ctDNA ...

Studying cancer DNA in blood may help personalize treatment in liver cancer

November 2, 2015
Fragments of cancer DNA circulating in a patient's bloodstream could help doctors deliver more personalized treatment for liver cancer, Japanese researchers report.

Blood test that monitors dead cancer cell DNA better at tracking spread of melanoma

January 11, 2016
Physicians treating patients with metastatic melanoma—one of the most aggressive forms of skin cancer—may soon have a superior tool in their efforts to closely track the disease.

Recommended for you

Could the zika virus fight the brain cancer that killed john McCain?

September 18, 2018
(HealthDay)—Preliminary research in mice suggests that the Zika virus might be turned from foe into friend—enlisted to curb deadly glioblastoma brain tumors.

Eating foods with low nutritional quality ratings linked to cancer risk in large European cohort

September 18, 2018
The consumption of foods with higher scores on the British Food Standards Agency nutrient profiling system (FSAm-NPS), reflecting a lower nutritional quality, is associated with an increased risk of developing cancer, according ...

CRISPR screen reveals new targets in more than half of all squamous cell carcinomas

September 18, 2018
A little p63 goes a long way in embryonic development—and flaws in p63 can result in birth defects like cleft palette, fused fingers or even missing limbs. But once this early work is done, p63 goes silent, sitting quietly ...

Enlarged genotype-phenotype correlation for a three-base pair deletion in neurofibromatosis type 1

September 18, 2018
International collaborative research led by Ludwine Messiaen, Ph.D., shows that while a three-base pair, in-frame deletion called p.Met992del in the NF1 gene has a mild phenotype for people with the genetic disorder neurofibromatosis ...

Artificial intelligence can determine lung cancer type

September 17, 2018
A new computer program can analyze images of patients' lung tumors, specify cancer types, and even identify altered genes driving abnormal cell growth, a new study shows.

Researchers develop mechanism for characterizing function of rare tumor cells

September 17, 2018
Scientists have long known that circulating tumor cells, rare cancer cells that are released into the bloodstream, have the potential to provide vital information about a person's specific cancer. But until now, they have ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.